We developed screening tests to identify molecules that inhibit the resistance to doxorubicin (dxr), a chemotherapeutic agent used to treat many cancers, conferred by human Ptch1 to yeast, and the efflux of dxr by Ptch1 [18]. The gene discussed is PTCH1; the disease is cancer.